“The SFC has serious concerns that Cloudbreak’s initial public offering may have been rigged to create an artificial impression of demand for Cloudbreak’s shares,” the SFC said in a statement on Thursday. The regulator considered the suspension “necessary or expedient to maintain an orderly and fair market” for the firm’s shares and to “protect the…
The recent news about China developing the world’s fastest supercomputer will trigger the predictable debate about whether Beijing has finally overtaken the US in advanced computing. The answer, at least for now, is no. The new LineShine system that topped the latest TOP500 ranking is not the world’s most powerful machine for artificial intelligence (AI)…
David Ricks, chief executive officer of Eli Lilly & Co., speaks during the China Development Forum in Beijing in March this year. Photographer: Qilai Shen/Bloomberg © 2026 Bloomberg Finance LP In the latest China pharmaceutical industry collaboration pact with a global drug leader, Abbisko said today it will work with U.S.-based Eli Lilly and Company…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE. Pfizer and SINOPHARM have entered into a new partnership to promote antifungal drug Diflucan in China. The collaboration also includes plans to work together on future Pfizer product launches in the Chinese market. The agreement focuses…
Twenty-two strategic enterprises have signed agreements with the Office for Attracting Strategic Enterprises (OASES) to open or expand operations in Hong Kong. The latest group marks the sixth cohort under the government’s flagship investment attraction initiative since its launch in 2022, bringing the total number of strategic partners to more than 120. The South China…
Global drug maker Pfizer and biotech firm Amgen, each valued at more than HK$1 trillion (US$153 billion), are among 22 strategic enterprises planning to open or expand offices in Hong Kong, the South China Morning Post has learned. A source said on Monday that these industry leaders were among companies from the fintech, cloud computing…
Scientists in China have solved a 140-year-old chemistry problem in a breakthrough that could overturn traditional production methods and slash the cost of cancer treatments and other expensive medicinal compounds. The research was co-led by Zhang Xiaheng, from the Chinese Academy of Sciences’ Hangzhou Institute for Advanced Study, and Xue Xiaosong, a professor with the…
Biopharma has finally begun catching up with the overall stock market, if the positive returns shown by the top three exchange traded funds (ETFs) since the spring are any indication. Over the past six months, shares of the top three biopharma ETFs have jumped well into double digits. The top biotech-focused ETF with $6.562 billion…